Forkhead box (FOX) proteins are a large family of transcription factors with diverse functions in development, aging and cancer. Recently, using Foxp1 conditional knock-out mice in which all Foxp1 isoforms are deleted, we found that loss of Foxp1 results in the abnormal development of T cells. During the transition from double-positive (DP) stage to single-positive (SP) stage in the thymus, Foxp1-deficient SP thymocytes acquire an activated phenotype prematurely and develop into peripheral CD4+ T and CD8+ T cells that exhibit an activated phenotype, increased apoptosis and readily produce cytokines upon T cell receptor (TCR) engagement. These data identify Foxp1 as a novel essential player in the generation of quiescent na ve T cells during thymocyte development. Based on our most recent findings, we hypothesize that Foxp1 also plays a critical role in regulating T cell activation. Specifically, the proposed studies will address: 1) Which TCR signaling pathway(s) does Foxp1 impact in regulating T cell activation? 2) What are the key targets of Foxp1 in T cells? 3) What are the critical roles of Foxp1 in mature T cell responses in vivo? Whereas regulating TCR signaling pathway(s) could be part of the mechanism of how Foxp1 regulates T cell activation, the research proposed will also define other Foxp1-dependent functions by delineating global changes in gene expression that contribute to the abnormal activated phenotype of Foxp1-deficient T cells and identifying Foxp1 target genes. Knowledge obtained from these studies will provide novel information for the design of new therapeutic strategies designed to manipulate T cell activation for the treatment of autoimmune and infectious diseases, cancer, and in vaccine development.

Public Health Relevance

Proper T lymphocyte activation is essential for effective immune responses to fight against infectious diseases and cancer. The complex transcriptional regulation of T cell activation is still poorly understood. The research on the understanding of transcriptional regulation of T cell activation by key factors will provide novel information in the design of new therapeutic strategies that would manipulate T cell activation for the treatment of autoimmune and infectious diseases, cancer, and in vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI088102-01A1
Application #
8308715
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Prabhudas, Mercy R
Project Start
2011-08-15
Project End
2012-08-14
Budget Start
2011-08-15
Budget End
2012-08-14
Support Year
1
Fiscal Year
2011
Total Cost
$423,250
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104